A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences. (1st July 2021)

• Record Type: Journal Article
• Authors: Dessinioti, C.; Geller, A.C.; Stergiopoulou, A.; Dimou, N.; Lo, S.; Keim, U.; Gershenwald, J.E.; Haydu, L.E.; Dummer, R.; Mangana, J.; Hauschild, A.; Egberts, F.; Vieira, R.; Brinca, A.; Zalaudek, I.; Deinlein, T.; Evangelou, E.; Thompson, J.F.; Scolyer, R.A.; Peris, K.; Garbe, C.; Stratigos, A.J.
• Is Part Of: British journal of dermatology. Volume 185:Number 1(2021)
• Page Start: 101
• Page End: 109
• Publication Date: 2021-07-01
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.19819
• Languages: English
• ISSNs: 0007-0963

Abstract

Summary: Background: Whether melanoma in histological contiguity with a naevus [naevus‐associated melanoma (NAM)] is distinctly different from melanoma arising de novo remains unclear. Objectives: To determine whether the characteristics of de novo melanoma differ from NAM and are not due to naevus obliteration in thicker tumours. Methods: We conducted a multicentre retrospective study of de novo melanoma and NAM in seven referral centres in Europe, Australia and the USA between 2006 and 2015. Results: In a total of 9474 localized melanomas, de novo melanoma was associated with thicker tumours and body site differences compared with NAM. In the subset of T1 melanomas ( n = 5307), similar body site differences were found in multivariate analysis by body site. When compared with NAM, de novo melanoma was more likely to affect older individuals (≥ 70 years) when located on the head/neck [odds ratio (OR) 4·65, 95% confidence interval (CI) 2·55–8·46], the trunk (OR 1·82, 95% CI 1·40–2·36) or the upper extremity (OR 1·69, 95% CI 1·14–2·50), was more likely to affect female patients when located on the lower extremities (OR 1·36, 95% CI 1·03–1·80), and was more likely to be of the nodular melanoma subtype (OR 2·23, 95% CI 1·14–4·35) when located on the trunk. De novo melanoma was less likely to have regression present compared with NAM. Conclusions: Clinicopathological and body site differences between de novo melanoma and NAM support the divergent pathway model of development. These differences were also found in thin melanomas, suggesting that de novo melanomas are different from NAM and their differences are not due to the obliteration of naevus remnants in thicker tumours.